Recruiting

Observational Study

Sponsor:

AO Innovation Translation Center

Code:

NCT02790983

Conditions

Spinal Column Tumor

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This project aims to establish a network of spine oncology centers dedicated to prospective multicenter research of patients diagnosed with a primary tumor of the spine and will include a comprehensive prospective clinical database which will serve as a shared research platform. Demographic, clinical, diagnostic, and therapeutic variables will be used to answer questions about survival and local recurrence, as well as questions about adverse events (AEs), morbidity data, and health-related quality of life (HRQOL) outcomes.

Conditions

Spinal Column Tumor

Study ID

NCT02790983

Start date

Oct, 2016

Status verified date

Feb, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion criteria

  • Patient with a current primary spine tumor or history of a primary spine tumor, including tumors within or surrounding the spinal column and/or spinal cord. This includes extradural tumors, intramedullary tumors (i.e. astrocytomas, ependymoma, etc.) and extramedullary tumors (i.e. meningiomas, neurofibromas, schwannomas, etc.).
  • Informed consent obtained, i.e.:

  • Ability to understand the content of the patient information/ICF
  • Willingness and ability to participate in the registry according to the Registry Plan (RP)
  • Signed and dated EC/IRB approved written informed consent

OR

  • Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide independent written informed consent

Exclusion Criteria:

\- Patient diagnosed with a metastatic tumor of the spine.

Study Design

Enrollment

1350 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Overall survival data [ Time Frame: From the date of enrollment until the date of dropout (ie. consent withdrawal, lost-to follow-up or death) which can be up to 25 years ]
  • Local disease recurrence data [ Time Frame: From the date of enrollment until the date of dropout (ie. consent withdrawal, lost-to follow-up or death) which can be up to 25 years ]
  • Perioperative morbidity data [ Time Frame: From the date of enrollment until the date of dropout (ie. consent withdrawal, lost-to follow-up or death) which can be up to 25 years ]

Central Contacts and Locations

Central contacts

Felix Thomas, PhD

+41 79 671 47 98felix.thomas@aofoundation.org

Mariana Cabeleira

+41 79 671 47 98mariana.cabeleira@aofoundation.org

Locations

UCSF Medical Center

Recruiting

San Francisco, California, United States, 94134

Contacts

Praveen Mummaneni, MD

+1 415-353-7500praveen.mummaneni@ucsf.edu

Johns Hopkins University School of Medicine

Recruiting

Baltimore, Maryland, United States, 21205

Contacts

Chetan Bettegowda, MD

cbetteg1@jhmi.edu

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

John H Shin, MD

Shin.John@mgh.harvard.edu

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Michelle Clarke, MD

Clarke.Michelle@mayo.edu

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 1275

Contacts

Ori Barilai, MD

barzilao@mskcc.org

Rhode Island Hospital

Recruiting

Providence, Rhode Island, United States, 02903

Contacts

Ziya L. Gokaslan, MD

ziya_gokaslan@brown.edu

The University of Texas M.D. Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Laurence D. Rhines, MD

lrhines@mdanderson.org

Vancouver General Hospital and the University of British Columbia

Recruiting

Vancouver, British Columbia, Canada, V5Z 1M9

Contacts

Nicolas Dea, MD

nicolas.dea@vch.ca

More Information

Sponsor

AO Innovation Translation Center

Last update posted

Feb 25, 2026

Last verified

Feb, 2026

Keywords

  • Registry
  • Spine
  • Surgery
  • Medical Oncology
  • Radiation Oncology
  • Neoplasms
  • Systemic Oncologic Therapy
  • Radiation Therapy
  • Tumor Markers

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by AO Innovation Translation Center on 2026-02-25.